Reid Laurence 4

What Happened

• Reid Laurence, a director of Metagenomi Therapeutics, was granted a derivative award for 17,400 shares on 2026-06-09. The grant is reported at $0.00 per share (i.e., no cash paid at grant). This was an award/option-type grant (transaction code A), not a market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (timely filing).
• Quantity: 17,400 shares reported as a derivative award; reported price per share: $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award vests on the earlier of (i) the one‑year anniversary of the grant date or (ii) the Company’s 2027 annual meeting of stockholders, subject to Laurence’s continued service.
• Transaction type/code: A = Award/Grant (derivative).

Context

• This is a standard equity incentive grant to a director; it does not represent an open‑market purchase or sale and is not indicative of a taxable sale or immediate cash event. The award vests over time contingent on continued service, so any future exercises or sales would be reported separately.